Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01695616

Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms

A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms.

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Ache Laboratorios Farmaceuticos S.A. · Industry
Sex
Female
Age
40 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effects of Passiflora incarnata and Isoflavone combination in relieving the symptoms associated with Climacteric Syndrome.

Detailed description

It is known that Hormone Therapy is recommended postmenopausal women to reduce menopausal symptoms and prevent osteoporosis frames and cardiovascular disease. However, only 30 to 40% of women still using hormone therapy. One reason women do not continue or are reluctant to start Hormone Therapy is realizing that the prescription of hormones is not a natural situation. Therefore, there is an increased interest in the use and prescription of estrogen derived from plants, known as fitoestrogênios. The development of a drug containing two standardized extracts was focused on two main symptoms of menopause: hot flashes and anxiety. This product comes from a longing for the doctors themselves can respond more promptly to patients who reach menopause and who already has a framework for mild to moderate anxiety. Thus, to meet the woman who develops menopausal symptoms and that these two are highly prevalent during menopause, causing intense discomfort routine for this woman, was produced in association with Soy Passiflora aiming to control anxiety and hot flushes

Conditions

Interventions

TypeNameDescription
DRUGPlacebo
DRUGActive drug

Timeline

Start date
2013-08-01
Primary completion
2014-08-01
Completion
2015-03-01
First posted
2012-09-28
Last updated
2016-10-19

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01695616. Inclusion in this directory is not an endorsement.